Cooperative Agreement U01CA274996
Award Date 9/15/22
Completion Date 8/31/28
Dollars Obligated $3.9M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Philadelphia, PA 19103, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...
- Summary of Federal Cooperative Agreement Award The University of California, San Francisco (UCSF) received a $5.04 million Cooperative Agreement from the National Cancer Institute under the Cancer Centers Support Grants program (CFDA 93.397) awarded August 1, 2025, with completion scheduled for July 31, 2030. The UCSF Cancer Health Disparities (CHD) Specialized Program of Research Excellence (SPORE) investigates the interplay of tumor genomic and immune characteristics with individual risk...
- Cooperative Agreement Summary Wake Forest University Health Sciences received a $248,194 Cooperative Agreement from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) to prepare for a multisite efficacy trial addressing communication barriers between radiation oncologists and radiologists in cancer treatment planning and surveillance. The award, effective May 1, 2025, through April 30, 2028, funds the development and feasibility testing of the...
- This federal Project Grant award, totaling $477,869.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant aims to develop tailored, multilevel cervical cancer interventions for ethnically diverse Black women, including African American women and Black African immigrant women. The key objectives are to: 1) identify multilevel determinants of routine cervical cancer screening and follow-up adherence among these populations,...
- Federal Project Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $404,974 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), effective September 1, 2025 through August 31, 2027. The grant supports research evaluating the adoption, implementation, and maintenance of thermal ablation (TA) as a cervical precancer treatment in El Salvador. This research addresses a...
- This federal Project Grant award of $589,591.00 from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) aims to determine how social factors may explain poorer survival outcomes for Black and Hispanic patients with Hodgkin lymphoma. The key products and services to be delivered under this 5-year project include: Examining differences in the receipt and quality of Hodgkin lymphoma treatment for initial diagnosis and relapse for those who have...
- This Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), will fund a study to evaluate the impact of social determinants of health (SDOH) on early-onset colorectal cancer (EOCRC) diagnosis, treatment delays, and survival, with a focus on underserved populations in Kentucky and Georgia. The $192,610 award will support a 2-year epidemiologic study that aims to elucidate the relationship between SDOH measures and...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a Project Grant of $807,644 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on August 13, 2025, to develop and pilot the DESCANSO (Depression, Fatigue, and Sleep) intervention. DESCANSO is a culturally adapted cognitive behavioral therapy (CBT) treatment designed to address the co-occurring symptom cluster of depression, insomnia, and fatigue in Spanish-speaking...
- Federal Project Grant Award Summary The University of Colorado-Denver received a $547,080 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on September 17, 2025, with an ultimate completion date of August 31, 2029. Under the direction of Dr. Wood, the Deputy Director of the Cancer Control Program, this award supports the University of Colorado Cancer Center's (UCCC) efforts to advance cancer screening and prevention trials....
- This Project Grant award, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), will fund research at the University of California, San Francisco (UCSF) aimed at investigating the biological mechanisms behind racial disparities in head and neck cancer outcomes, particularly among Black patients. The $714,062 grant, awarded on April 15, 2025, with a completion date of March 31, 2030, will support two key research objectives: 1) Developing a tailored RNA prognostic model...